Tempus AI and Recursion Pharmaceuticals extended their data license agreement through November 2029 and revised the contract's fee structure. Up to $84 million in discretionary payments over ...
Opinion
15hOpinion
Databricks CEO Ali Ghodsi analyzes the 'pacing' debate as a 'PR failure' — 'They should have just said they were strengthening security'
Databricks CEO Ali Ghodsi shared his in-depth perspective on the recent AI safety debate in a podcast. He analyzed Dario Amodei's 'pacing' proposal from a PR perspective, presented his own 'four ...
Tempus AI has an average rating of overweight and mean price target of $67.94, according to analysts polled by FactSet.
British Columbia sued OpenAI in California on Monday, saying a mass shooting at a school in the province could have been prevented if the company had warned local law enforcement that the shooter had ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results